Korean Circ J.  2025 Feb;55(2):151-160. 10.4070/kcj.2024.0002.

Early Versus Late Post Cesarean Section Warfarin Initiation and Increased Risk of Maternal Complications in Patients With Mechanical Heart Valves: A Randomized, Open-Label Pilot Study

• Youssef G
• Mohamed TEH
• Raouf MAA
• Tammam ASF
• Gabr AA

• KMID: 2565421
• DOI: http://doi.org/10.4070/kcj.2024.0002

Abstract

Background and Objectives
The timing of the reinstitution of warfarin after cesarean section (CS) delivery was not adequately addressed in the literature. This study aims to evaluate the risks of early versus late initiation of warfarin post-CS in patients with mechanical heart valves.
Methods
This randomized, open-label cohort study included 114 pregnant women with mechanical heart valves planned to be delivered by CS at or after 28 weeks of gestation. Patients were randomly divided into two groups: Day-2-group, where warfarin was started on day 2, and Day-5-group, where warfarin was started on day 5 after CS. Maternal postoperative bleeding complications, mechanical valve thrombosis, need for blood transfusion or reoperation, and maternal mortality were identified.
Results
Ten women (8.8%) had 11 bleeding complications, of whom 2 patients (20%) had intraperitoneal hemorrhage (none in Day-2-group and 2 in Day-5-group), 3 patients (30%) had subcutaneous hematoma (none in Day-2-group and 3 in Day-5-group), and 6 patients (60%) had sub-rectus hematoma (3 in Day-2-group and 3 in Day-5-group). No mechanical valve thrombosis, other thromboembolic events, or in-hospital maternal mortality were reported.
Conclusion
Despite the small number of events, the bleeding risk was lower in the group with early post-CS warfarin introduction than in the group with late warfarin introduction in patients with prosthetic heart valves.

Keyword

Heart valve prosthesis; Warfarin; Postpartum hemorrhage

Figure

• 

  Figure 1 Postoperative bleeding complications in the 2 study groups.IP = intraperitoneal hematoma; SC = subcutaneous hematoma; SR = subrectus hematoma.

Reference

1. McLintock C. Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: no easy option. Thromb Res. 2011; 127(Suppl 3):S56–S60. PMID: 21262443.

2. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39:3165–3241. PMID: 30165544.

3. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022; 43:3826–3924. PMID: 36017553.

4. Lester W, Walker N, Bhatia K, et al. British Society for Haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves. Br J Haematol. 2023; 202:465–478. PMID: 37487690.

5. Allen M, Sevensma KE. Rectus sheath hematoma. Treasure Island (FL): StatPearls Publishing;2022.

6. Fawcus S, Moodley J. Postpartum haemorrhage associated with caesarean section and caesarean hysterectomy. Best Pract Res Clin Obstet Gynaecol. 2013; 27:233–249. PMID: 23084097.

7. Hanania G. Management of anticoagulants during pregnancy. Heart. 2001; 86:125–126. PMID: 11454818.

8. Bhagra CJ, D’Souza R, Silversides CK. Valvular heart disease and pregnancy part II: management of prosthetic valves. Heart. 2017; 103:244–252. PMID: 27670966.

9. Arya R. Pregnancy outcomes in women with mechanical prosthetic heart valves. Thromb Res. 2019; 181(Suppl 1):S37–S40. PMID: 31477226.

10. Irani RA, Santa-Ines A, Elder RW, Lipkind HS, Paidas MJ, Campbell KH. Postpartum anticoagulation in women with mechanical heart valves. Int J Womens Health. 2018; 10:663–670. PMID: 30498374.

11. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143:e35–e71. PMID: 33332149.

12. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003; 41:1633–1652. PMID: 12742309.

13. Suen K, Westh RN, Churilov L, Hardidge AJ. Low-molecular-weight heparin and the relative risk of surgical site bleeding complications: results of a systematic review and meta-analysis of randomized controlled trials of venous thromboprophylaxis in patients after total joint arthroplasty. J Arthroplasty. 2017; 32:2911–2919.e6. PMID: 28522244.

14. Mathew PJ, Jehan F, Kulvatunyou N, et al. The burden of excess length of stay in trauma patients. Am J Surg. 2018; 216:881–885. PMID: 30082028.

15. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e691S–e736S. PMID: 22315276.